A Long New Review Makes the Case for BPC-157 in Liver Injury. Read Its Last Paragraph First.

A substantial review of BPC-157 and liver injury appeared in Pharmaceuticals on 1 October 2026. It runs through acetaminophen and carbon tetrachloride poisoning, bile duct ligation, alcohol-induced liver damage and portal hypertension, comparing BPC-157 against a long list of established and experimental agents: N-acetylcysteine, ursodeoxycholic acid, corticosteroids, resveratrol, curcumin, sildenafil, melatonin, simvastatin, stem cell approaches and others.

It is the most thorough gathering of this particular literature we have seen. It is also, by its own account, entirely preclinical. Both of those things are worth reporting together.

What the review reports

The organising idea is cytoprotection: the proposal that protecting tissue is not specific to one organ or one kind of injury, and that an agent which protects in one setting may protect in others.

Within that frame, the authors report that across the models they surveyed, BPC-157 showed protective and restorative effects, and that the reported actions extend beyond liver cells themselves to the lining of blood vessels, to microcirculation, to clotting, and to the activation of collateral vessels. They give particular weight to findings on portal hypertension — raised pressure in the vein carrying blood to the liver, a major complication of cirrhosis — reporting prevention and reversal in experimental models of several types.

Their proposed reading is that BPC-157 should be considered an experimental cytoprotective and vascular-restorative candidate rather than simply another hepatoprotective antioxidant.

The last paragraph

Reviews like this are often quoted selectively. So here is where the authors themselves land, in their own words:

"Nevertheless, the evidence remains predominantly preclinical, and further independent experimental and clinical studies are required to establish its pharmacological profile, safety, therapeutic efficacy, and applicability to human liver disease."

They go on to describe BPC-157 as a candidate for further translational investigation, independent replication, and phase II/III safety and efficacy data. In other words: the authors who assembled the most favourable case are explicit that the case is not yet a clinical one.

Who wrote it, and why that is worth noting

The review comes from departments of pharmacology, pathology and surgery at the University of Zagreb. The text refers at one point to "our reviewed findings" and to findings "obtained in collaboration with other labs," alongside work by independent groups.

That is not a criticism, and it is not hidden; it is stated in the paper. But our editorial standard is to say when a body of evidence is substantially the work of parties with an interest in the result, because it changes how much independent replication a reader should want before treating a conclusion as settled. The authors ask for exactly that replication themselves.

A narrative review also differs from a systematic one. A systematic review pre-registers its question and search, and reports everything that meets its criteria, including null results. A narrative review selects and synthesises. Both are legitimate; they answer different questions.

The contrast worth holding

Put this review next to the systematic review of BPC-157 in humans published in Acta Orthopaedica Belgica in October, which we covered on 30 October. That one searched for every human study of BPC-157 for any purpose, and found three, with 30 participants in total: a retrospective study of BPC-157 given into the knee joint for pain, a retrospective pilot in interstitial cystitis, and a two-person safety pilot. It graded the overall certainty of evidence as very low.

So the state of play is: a large, varied and in places internally consistent animal literature, and a human literature of thirty people across three uncontrolled studies. The liver review does not contradict that. It occupies the other side of the same gap.

A narrative review in Current Pain and Headache Reports this August reached a compatible conclusion across the regenerative peptides generally: most remain unapproved, clinical evidence in humans is limited, and use should be guided by careful clinical judgement.

What has not been studied

• No clinical trial of BPC-157 in human liver disease appears in this review.
• The portal hypertension findings, which the authors highlight, are from animal models only.
• How BPC-157 is absorbed, distributed and cleared in people remains uncharacterised.
• No long-term human safety data exist.

What to watch

The review names what would move this forward: independent replication, and phase II/III data. Those are the results worth waiting for. An additional animal model, however favourable, would not change the shape of the evidence.

Sources

1. Sever M, et al. Possibilities for Cytoprotective Liver Therapy, Stable Gastric Pentadecapeptide BPC 157, and Standard Agents — A Narrative Review. Pharmaceuticals (2026)
2. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica (2026)
3. Luansritisakul C, et al. Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. Curr Pain Headache Rep (2026)

Compounds in this article

BPC-157